Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease
Interventions
Group 1 ELND005, Group 2 ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Conditions
Macular Degeneration
Interventions
bevasiranib, ranibizumab
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
Conditions
Diabetic Macular Edema
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Beechwood, Ohio
Conditions
Diabetes Mellitus, Type 2
Interventions
TT223 with Metformin and/or TZD, Placebo with Metformin and/or TZD
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Artesia, California • Los Angeles, California • Santa Ana, California + 17 more
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions
Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bannockburn, Illinois
Conditions
Benign Prostatic Hyperplasia
Interventions
Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo
Drug · Other
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Anniston, Alabama • Lincoln, California • Sacramento, California + 12 more
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions
CTAP101, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Columbus, Ohio • Greenville, South Carolina
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Conditions
Prostate Cancer
Interventions
Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged
Diagnostic Test
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
64 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hemophilia A, Hemophilia B
Interventions
MOD-5014
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 7 more
Conditions
Macular Degeneration
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Conditions
Growth Hormone Deficiency (GHD)
Interventions
MOD-4023
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Conditions
Growth Hormone Deficiency
Interventions
MOD-4023, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2944876, Exenatide extended-release, Placebo, Metformin
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Concord, California • Fresno, California • Los Angeles, California + 27 more
Conditions
COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions
Rayaldee, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
Conditions
Bipolar 1 Disorder
Interventions
ELND005, Lamotrigine, Valproic acid, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
Conditions
Type 2 Diabetes Mellitus
Interventions
OPK-88003, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Huntington Park, California • Los Angeles, California • Hialeah, Florida
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

NCT07512427
Conditions
MASH
Interventions
OPK-88006, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Conditions
Alzheimer's Disease
Interventions
ELND005 (scyllo-inositol)
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 27 more
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP101 Capsules, CTAP101 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more